174 related articles for article (PubMed ID: 16922969)
21. Intertrigo-like dermatitis with pegylated liposomal doxorubicin: diagnosis and management.
Najem A; Deregnaucourt D; Ramdane S; Dridba M; Djouba F; Vercambre-Darras S
J Clin Oncol; 2014 Nov; 32(31):e104-6. PubMed ID: 24550424
[No Abstract] [Full Text] [Related]
22. Grade 3 liposomal-doxorubicin-induced skin toxicity in a patient following complete resolution of moderately severe sunburn.
Markman M; Kulp B; Peterson G
Gynecol Oncol; 2004 Aug; 94(2):578-80. PubMed ID: 15297208
[TBL] [Abstract][Full Text] [Related]
23. Pyridoxine as prophylactic therapy for palmar-plantar erythrodysesthesia associated with administration of pegylated liposomal doxorubicin (caelyx): a single-center experience.
Rossi D; Catalano G
Oncology; 2007; 73(3-4):277-8. PubMed ID: 18424894
[No Abstract] [Full Text] [Related]
24. Phase II trial of biweekly pegylated liposomal doxorubicin in recurrent platinum-refractory ovarian and peritoneal cancer.
Strauss HG; Hemsen A; Karbe I; Lautenschläger C; Persing M; Thomssen C
Anticancer Drugs; 2008 Jun; 19(5):541-5. PubMed ID: 18418221
[TBL] [Abstract][Full Text] [Related]
25. Recall inflammatory skin reaction after use of pegylated liposomal doxorubicin in site of previous drug extravasation.
Saini A; Berruti A; Sperone P; Bitossi R; Tampellini M; Dogliotti L; Gorzegno G
Lancet Oncol; 2006 Feb; 7(2):186-7. PubMed ID: 16455484
[No Abstract] [Full Text] [Related]
26. Pegylated liposomal doxorubicin in ovarian cancer.
Green AE; Rose PG
Int J Nanomedicine; 2006; 1(3):229-39. PubMed ID: 17717964
[TBL] [Abstract][Full Text] [Related]
27. Pegylated liposomal doxorubicin-induced palmar-plantar erythrodysestesia in multiple uncommon sites.
Corazza M; Minghetti S; Zauli S; Ricci M; Borghi A; Virgili A
Eur J Dermatol; 2011; 21(3):433-4. PubMed ID: 21515437
[No Abstract] [Full Text] [Related]
28. Chemotherapy-induced palmer planter erythrodysesthesia.
Bhasin S; Sunita ; Gupta DK; Kataria SP; Saluja S; Sharma M
J Assoc Physicians India; 2005 Feb; 53():155-6. PubMed ID: 15847041
[TBL] [Abstract][Full Text] [Related]
29. [Intertriginous rash caused by pegylated liposomal doxorubicin].
Monteagudo B; Afonso-Afonso FJ; Cabanillas M; Used-Aznar MM
Actas Dermosifiliogr; 2009 Apr; 100(3):241-2. PubMed ID: 19457315
[No Abstract] [Full Text] [Related]
30. Granular parakeratosis in a patient treated with liposomal doxorubicin for ovarian carcinoma.
Jaconelli L; Doebelin B; Kanitakis J; Saïd BB; Faure M; Claudy A
J Am Acad Dermatol; 2008 May; 58(5 Suppl 1):S84-7. PubMed ID: 18489055
[TBL] [Abstract][Full Text] [Related]
31. Paclitaxel, carboplatin and pegylated liposomal doxorubicin in ovarian and peritoneal carcinoma: a phase I study of the Gynecologic Oncology Group.
Rose PG; Greer BE; Horowitz IR; Markman M; Fusco N
Gynecol Oncol; 2007 Jan; 104(1):114-9. PubMed ID: 16959305
[TBL] [Abstract][Full Text] [Related]
32. Varenicline-induced drug eruption with resulting palmar/plantar hyperhidrosis and dysesthesia.
Nicholas MW; Isenstein A; Dasher D; Granko RP; Lugo-Somolinos A; Groben P; Morrell DS
J Am Acad Dermatol; 2010 Jul; 63(1):e5-7. PubMed ID: 20542171
[No Abstract] [Full Text] [Related]
33. Phase II clinical trial of pegylated liposomal doxorubicin (JNS002) in Japanese patients with mullerian carcinoma (epithelial ovarian carcinoma, primary carcinoma of fallopian tube, peritoneal carcinoma) having a therapeutic history of platinum-based chemotherapy: a Phase II Study of the Japanese Gynecologic Oncology Group.
Katsumata N; Fujiwara Y; Kamura T; Nakanishi T; Hatae M; Aoki D; Tanaka K; Tsuda H; Kamiura S; Takehara K; Sugiyama T; Kigawa J; Fujiwara K; Ochiai K; Ishida R; Inagaki M; Noda K
Jpn J Clin Oncol; 2008 Nov; 38(11):777-85. PubMed ID: 18927230
[TBL] [Abstract][Full Text] [Related]
34. A phase-I study evaluating the combination of pegylated liposomal doxorubicin and paclitaxel as salvage chemotherapy in metastatic breast cancer previously treated with anthracycline.
Hong RL; Lin CH; Chao TY; Kao WY; Wang CH; Hsieh RK; Hwang WS
Cancer Chemother Pharmacol; 2008 Apr; 61(5):847-53. PubMed ID: 17609947
[TBL] [Abstract][Full Text] [Related]
35. Pegylated liposomal doxorubicin-associated hand-foot syndrome: recommendations of an international panel of experts.
von Moos R; Thuerlimann BJ; Aapro M; Rayson D; Harrold K; Sehouli J; Scotte F; Lorusso D; Dummer R; Lacouture ME; Lademann J; Hauschild A
Eur J Cancer; 2008 Apr; 44(6):781-90. PubMed ID: 18331788
[TBL] [Abstract][Full Text] [Related]
36. Exfoliative dermatitis during cefoxitin therapy.
Kannangara DW; Smith B; Cohen K
Arch Intern Med; 1982 May; 142(5):1031-2. PubMed ID: 6211152
[TBL] [Abstract][Full Text] [Related]
37. Erythrodermic drug eruption due to roxatidine acetate hydrochloride.
Igawa K; Matsunaga T; Yokozeki H; Nishioka K
Clin Exp Dermatol; 2005 May; 30(3):304-5. PubMed ID: 15807703
[No Abstract] [Full Text] [Related]
38. Pegylated liposomal doxorubicin and carboplatin in late-relapsing ovarian cancer: a GINECO group phase II trial.
Weber B; Lortholary A; Mayer F; Bourgeois H; Orfeuvre H; Combe M; Platini C; Cretin J; Fric D; Paraiso D; Pujade-Lauraine E
Anticancer Res; 2009 Oct; 29(10):4195-200. PubMed ID: 19846972
[TBL] [Abstract][Full Text] [Related]
39. [Ovarian carcinoma. Residual therapy with pegylated liposomal doxorubicin?].
Musch A
Med Monatsschr Pharm; 2005 Dec; 28(12):453-5. PubMed ID: 16389880
[No Abstract] [Full Text] [Related]
40. Phase 1 clinical study of pegylated liposomal doxorubicin (JNS002) in Japanese patients with solid tumors.
Fujisaka Y; Horiike A; Shimizu T; Yamamoto N; Yamada Y; Tamura T
Jpn J Clin Oncol; 2006 Dec; 36(12):768-74. PubMed ID: 17095524
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
